Exousia Pro, Inc., a clinical-stage biotech company that specializes in the use of exomes to treat cancer and other illnesses ...

An exosome-based treatment of glioblastoma multiforme (GBM) has received orphan drug designation from the FDA. 1 Exousia AI, ...

BEIJING & BURLINGTON, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and ...

Exousia Pro is in a unique position, as only 11% of ODAs are awarded at the preclinical stage. ORLANDO, FLORIDA / ACCESS Newswire / October 28, 2025 / Exousia Pro, Inc. (formerly Marijuana, Inc.) ...

Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

BOSTON--(BUSINESS WIRE)--BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that patients have been initially dosed in its Phase 2 ...

Half of patients with GBM present with headaches at diagnosis, which is attributed to increases in intracranial pressure (Table 2). 11 Papilledema, now rarely seen because imaging is typically ...

BRISBANE, Australia, Oct. 7, 2025 /PRNewswire/ -- Cyteph Pty Ltd, a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully ...

Georgina Maynard was diagnosed with a glioblastoma multiforme, the most common and aggressive type of brain tumour, in May 2023 - John Lawrence In May 2023, Georgina Maynard was diagnosed with a brain ...